Journal
LANCET
Volume 388, Issue 10048, Pages 1012-1024Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/S0140-6736(16)31473-8
Keywords
-
Categories
Funding
- University of Colorado from Genentech
- BMS
- Lilly
- Amgen
- Bayer
- Claris
- AstraZeneca
- Merck
- Novartis
- Pfizer
- Genentech/Roche
- Celgene
- Daiichi
Ask authors/readers for more resources
Targeted therapies are substantially changing the management of lung cancers. These treatments include drugs that target driver mutations, those that target presumed important molecules in cancer cell proliferation and survival, and those that inhibit immune checkpoint molecules. This area of research progresses day by day, with novel target discoveries, novel drug development, and use of novel combination treatments. Researchers and clinicians have also extensively investigated the predictive biomarkers and the molecular mechanisms underlying inherent or acquired resistance to these targeted therapies. We review recent progress in the development of targeted treatments for patients with advanced non-small-cell lung cancer, especially focusing on data from published clinical trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available